The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

FDA tentatively OKs cabozantinib capsules for RCC, HCC and epNET, with dose-conversion guidance, error warning and improved ...

ASCO updates stage IV NSCLC guidance, adding repotrectinib and zongertinib, with trial-backed dosing and sequencing tips for ...

Incorporating tucatinib into HP maintenance more than doubled PFS in patients with brain metastases, addressing limited blood–brain barrier penetration of many HER2-directed antibodies. Outside the ...

July 2026 brought a dense run of FDA activity across breast, lung, bladder, and blood cancers, along with a pancreatic cancer application that moved through review in a matter of ...

Dr. Monty Pal discusses how patient- and disease-specific characteristics influence treatment sequencing decisions for advanced renal cell carcinoma (RCC) beyond the first-line setting.

Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent ...

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 in favor of the IGNYTE study (NCT03767348) supporting the potential accelerated approval of vusolimogene oderparepvec (RP1; ...

Dual fast track and RMAT designations enable more frequent FDA engagement and potentially accelerated development for MRD-positive LBCL consolidation after first-line response. ALPHA3 randomizes ctDNA ...

Priority review positions subcutaneous amivantamab as a potential first-in-class EGFR/MET-targeted option after platinum and PD-1/PD-L1 failure in HPV-unrelated R/M HNSCC. Blinded central review ...

ARTEMIS-011 randomized 117 patients 2:1 to risvutatug rezetecan 12.0 mg/m² IV q3w versus gemcitabine/docetaxel after failure of ≥2 prior systemic lines. Primary endpoint PFS was met with statistically ...

The single-arm trial met its primary end point of complete response (CR) at any time, exceeding historic and contemporary ...